BioCentury
ARTICLE | Company News

Catalent Pharma, Profectus infectious, biomanufacturing news

May 14, 2012 7:00 AM UTC

Profectus said it received a $5.6 million grant from NIH's National Institute of Allergy and Infectious Diseases (NIAID) to conduct preclinical development of a vaccine using soluble Hendra virus glycoprotein G for use in humans against either Nipah or Hendra virus infection. Profectus will collaborate with international academic partners to develop the vaccine. Profectus said it will also use Catalent's GPEx gene product expression technology to produce high yield mammalian cell lines for production of the soluble glycoprotein. ...